A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Cross-Over Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder.

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Cross-Over Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Mar 2012 Primary endpoint 'Abnormal-Involuntary-Movement-Scale' has not been met when data from all study sites are included.
    • 05 Mar 2012 Actual patient number (37) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top